RETA — Reata Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeLarge Cap
- $6.52bn
- $6.27bn
- $2.22m
Reata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results And Provides An Update On Clinical Development Programs
Reata Pharmaceuticals Inc expected to post a loss of $2.06 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Virgin Galactic, Kohl's, Ralph Lauren, Tesla
U.S. STOCKS ON THE MOVE-Tesla, VBI Vaccines, Ralph Lauren, Virgin Galactic
Reata Pharma up on PT hike, improved approval probability for genetic disorder drug
U.S. STOCKS ON THE MOVE-Occidental Petroleum, Riot Blockchain, Morgan Stanley, Tesla
U.S. STOCKS ON THE MOVE-Reata Pharma, Wells Fargo, MINISO, Intel
Reata Pharma jumps on FDA request for meeting on genetic disorder drug
Reata Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Reata Pharmaceuticals Reports Q1 GAAP Loss Per Share $1.86
Reata Pharmaceuticals Inc expected to post a loss of $2.10 a share - Earnings Preview
Brief: Reata Announces FDA Accepted For Filing The NDA For Bardoxolone For The Treatment Of Patients With Chronic Kidney Disease Caused By Alport Syndrome
Brief: Reata Announces The Appointments Of Christy Oliger And Shamim Ruff To Its Board Of Directors
Brief: Reata Pharmaceuticals Says Qtrly Adjusted Loss Per Share $1.25
Brief: Reata Pharmaceuticals Inc Submits NDA For Co’s Program Bardoxolone In Alport Syndrome
U.S. STOCKS ON THE MOVE-Chevron, BlackBerry, ReneSola
U.S. STOCKS ON THE MOVE-Norwegian Cruise Line, Lyft, Palantir, Sempra Energy
U.S. STOCKS ON THE MOVE-Trip.com, ZommInfo, Moderna